%PDF-1.4
%
40 0 obj
<>
endobj
37 0 obj
<>
endobj
124 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-24T15:42:33Z
2024-03-29T01:01:02-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T01:01:02-07:00
application/pdf
Heather
200659.may
uuid:ae283363-1dd1-11b2-0a00-b109277d8900
uuid:ae283366-1dd1-11b2-0a00-d30000000000
endstream
endobj
26 0 obj
<>
endobj
27 0 obj
<>
endobj
41 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
140 0 obj
[144 0 R]
endobj
141 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(development of dystrophic calcification. J Pediatr 1983;103:882-8.)Tj
-1.675 -1.25 Td
[(6.)-875 (Ansell BM. Management of polymyositis and dermatomyositis.)]TJ
1.675 -1.25 Td
(Clin Rheum Dis 1984;10:205-13.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (Oliveri MB, Palermo R, Mautalen C, Hubscher O. Regression of)]TJ
0 Tc 1.675 -1.25 Td
(calcinosis during diltiazem treatment in juvenile dermatomyositis. )Tj
0 -1.25 TD
(J Rheumatol 1996;23:2152-5.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (American Hospital Formulary Service \(AHFS\) Drug Information.)]TJ
1.675 -1.25 Td
[(Bethesda, MD: )54.8 (American Society of Health System Pharmacists;)]TJ
0 Tc 0 Tw T*
(1999:2347-9.)Tj
0.0249 Tw -1.675 -1.25 Td
[(9.)-875 (Pascale LR, Dubin )54.8 (A, Hof)17.8 (fman )17.7 (WS. Metabolism: clinical and)]TJ
1.675 -1.25 Td
(experimental. 1954;3:462.)Tj
-2.175 -1.25 Td
[(10.)-875 (Dent CE, Stamp )17.7 (TCB. )17.7 (T)34.9 (reatment of calcinosis circumscripta with)]TJ
2.175 -1.25 Td
(probenecid. BMJ 1972;1:216-8.)Tj
-2.1381 -1.25 Td
[(1)36.9 (1.)-875 (Meyers D. )17.7 (T)34.9 (reatment of calcinosis circumscripta and Raynaud\222)54.9 (s)]TJ
2.1381 -1.25 Td
[(phenomenon. Med J )54.9 (Australia 1976;2:457.)]TJ
30.825 17.5 Td
[(12.)-875 (Skuterud E, Sydnes OA, Haavik )17.7 (TK. Calcinosis in dermatomyositis)]TJ
2.175 -1.25 Td
(treated with probenecid. Scand J Rheumatol 1981;10:92-4.)Tj
-2.175 -1.25 Td
[(13.)-875 (Eddy MC, Leelawattana R, McAlister )17.7 (WH, )17.7 (Whyte MP)110.8 (. Calcinosis)]TJ
2.175 -1.25 Td
(universalis complicating juvenile dermatomyositis: resolution)Tj
T*
[(during probenecid therapy)64.9 (. J Clin Endocrinol Metab 1997;)]TJ
0 Tw T*
(82:3536-42.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (Whyte MP)110.7 (. )17.7 (T)34.8 (umoral calcinosis. In: Favus MJ, editor)54.8 (. Primer on the)]TJ
0 Tc 2.175 -1.25 Td
(metabolic bone diseases and disorders of mineral metabolism. 3rd)Tj
T*
(ed. Philadelphia: Lippincott-Raven; 1996:424-5.)Tj
-2.175 -1.25 Td
[(15.)-925 (Stark H, Eisenstein B, )17.7 (T)34.9 (ieder M, et al. Direct measurement of)]TJ
2.175 -1.25 Td
[(TP/GFR: )54.9 (A)-219.8 (simple and reliable parameter of renal phosphate)]TJ
T*
(handling. Nephron 1986;44:125-8.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:5)Tj
0 Tw -46.2952 -0.0313 Td
(1132)Tj
ET
0 0 0 0 scn
/GS0 gs
103.25 59.75 407.5 -10.83 re
f*
0.5 w
103.25 59.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
82 0 obj
<>
endobj
130 0 obj
<>
endobj
51 0 obj
<>
endobj
43 0 obj
<>
endobj
45 0 obj
<>
endobj
77 0 obj
<>stream
HV pUBBr@6d7t 3+ $r̐F"J, )t\pqY(VC"
jR" R%R@T,DX`z~{_ Py^_7;9+9e& WWR5
.]1Fp$ 9ekoIb @+Z@2}SuX+ "?#ߣjQo Ԉ_p+H|xh(ݲ>tYE<+-nQm}/xɄ(uiҲ壳RD:Ku3Td~p)6?QB=~,_Gz"B\Fm$`抋c;qva=(/A5ӐCۿr"c'cgbqP6ZDU,ojXh`:Gq?Kr]PZNN;E&ŭPv1ZwYM:Q➆p5؊Fb"AWl)Y&Ƀ;UQWka$p|8rn"HDk{n}}8\@ЄSD"џ'y-!GJ2\T/kP]*[2ܮӋA%̽^cJm'lΝ?q
u 1"#UYj(RQ+7D1Q#(Y %r#OkyUސ?)Jb"Afj5Z1ЌPu崢tZbmÕ@G`G2ձϑǓ6P2eoYύC4O,av's~=<@H@sWtчbFE(1Sr1_&j*:&,v‸&nl&d'LvfTB%ߑr4nyVJ)cJ@)[mvsҢW(~ uZWr|uҲl-_+jhAQۥ98L|ݹҹوM7^}6#yLpYe2No",##=8p%o.NZwfs!.==^*?}Ec&=3S/ `*Wi64S(X0f]S-5Ѓ?m4Zn<) I1?^~t`632t)emxXߝYm&1R!ub].eqC]ZB4@hK!"D֚W%>/6G2MV&y
c!'(oʰi9=OF0s,ԓj#ώCC 4\"6&m
ʵCVTZڡV^[-&*8m[Wq.1.<)y|?ewSIA:17qWHU[s˹;C8{\ǐR Oy2ojPaٹE8M'^q"UR;J_S'#-vvs
o+1~NTdϏAG"FRR